RESUMEN
Two patients from Eritrea, recently arrived in the Netherlands, presented with fever and were investigated for malaria. Bloodfilms showed spirochetes but no blood parasites. Louse-borne relapsing fever caused by Borrelia recurrentis was diagnosed. Treatment was complicated by severe Jarisch-Herxheimer reactions in both patients. Physicians should be aware of the possibility of B. recurrentis infection in migrant populations who travel under crowded conditions, especially after passing through endemic areas such as Ethiopia and neighbouring countries.
Asunto(s)
Antibacterianos/administración & dosificación , Borrelia/aislamiento & purificación , Ceftriaxona/administración & dosificación , Doxiciclina/administración & dosificación , Infestaciones por Piojos/diagnóstico , Pediculus/microbiología , Fiebre Recurrente/diagnóstico , Animales , Antibacterianos/efectos adversos , Borrelia/genética , Ceftriaxona/efectos adversos , ADN Bacteriano/genética , ADN Bacteriano/aislamiento & purificación , Doxiciclina/efectos adversos , Hipersensibilidad a las Drogas/prevención & control , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Eritrea , Femenino , Humanos , Infestaciones por Piojos/tratamiento farmacológico , Masculino , Países Bajos , ARN Ribosómico 16S/genética , Reacción en Cadena en Tiempo Real de la Polimerasa , Fiebre Recurrente/tratamiento farmacológico , Fiebre Recurrente/microbiología , Viaje , Resultado del Tratamiento , Adulto JovenRESUMEN
Rituximab (RTX) treatment in rheumatoid arthritis (RA) patients severely hampers humoral response after influenza vaccination as determined by haemagglutination inhibition assay (HI). It is not known whether HI reflects both immunoglobulin (Ig)M and IgG (subclass) influenza response, and whether IgM antibodies contribute to the low rate of influenza infection seen in RA patients. Twenty RA patients on methotrexate (MTX), 23 on RTX and 28 healthy controls (HC) received trivalent influenza subunit vaccination. Before and 28 days after vaccination, H1N1- and H3N2-specific antibodies were measured by HI and by IgM and IgG (subclass) enzyme-linked immunosorbent assay (ELISA). B cell activating factor (BAFF) levels were determined in serum samples before vaccination. Vaccination induced a significant increase of IgM and IgG (IgG1 and IgG3) antibodies against both strains in the HC and MTX groups (all P < 0·01), but not in the RTX group. HI correlated significantly in all cases with IgG (IgG1) but not with IgM. In RTX late patients (RTX treatment 6-10 months before vaccination), IgG (IgG1 and IgG3) response to vaccination was restored, but not IgM response. BAFF levels were significantly increased in RA-RTX patients and correlated with total IgG levels. Haemagglutination inhibition assay, used as gold standard, detects primarily IgG (IgG1) responses. IgM- and IgG influenza-specific antibodies increase after vaccination in HC and RA patients except in patients on RTX treatment. BAFF levels are increased in both early and late RTX-treated patients, but do not correlate with an influenza-specific antibody response.
Asunto(s)
Anticuerpos Monoclonales de Origen Murino/uso terapéutico , Artritis Reumatoide/tratamiento farmacológico , Artritis Reumatoide/inmunología , Inmunoglobulina G/inmunología , Inmunoglobulina M/inmunología , Vacunas contra la Influenza/administración & dosificación , Gripe Humana/inmunología , Anticuerpos Antivirales/inmunología , Femenino , Pruebas de Inhibición de Hemaglutinación/métodos , Humanos , Subtipo H1N1 del Virus de la Influenza A/inmunología , Subtipo H3N2 del Virus de la Influenza A/inmunología , Vacunas contra la Influenza/inmunología , Masculino , Metotrexato/uso terapéutico , Persona de Mediana Edad , Rituximab , Vacunación/métodosRESUMEN
OBJECTIVE: The spectrum of neuropsychiatric illness (NI) associated with the Human Immunodeficiency Virus (HIV) and/or the Hepatitis C Virus (HCV) is far reaching and significantly impacts the clinical presentation and outcome of infected persons; however, the etiological and pathophysiological background remains partially understood. The present work was aimed to investigate the potential significance of formin binding protein 1 (FNBP-1)-dependent pathways in NI-pathogenesis by elaborating on previous microarray-based research in HIV and/or HCV-infected patients receiving interferon-α (IFN-α) immunotherapy via a rigorous data mining procedure. METHODS: Using microarray data of peripheral whole blood (PB) samples obtained from HCV mono-infected persons (n=25, Affymetrix® HG-U133A_2) 12 h before and after the 1st dose of pegylated IFN-α (PegIFN-α), we re-applied the same analytical algorithm that we had developed and published in an earlier study with HIV/HCV co-infected subjects (N=28, Affymetrix® HG-U133A), in order to evaluate reproducibility of potential NI-related molecular findings in an independent cohort. RESULTS: Among 28 gene expression profiles (HIV/HCV: N=9 vs. HCV: N=19) selected by applying different thresholds (a Mean Fold Difference value (MFD) in gene expression of ≥ 0.38 (log2) and/or P value from <0.05 to ≤ 0.1) FNBP-1 was identified as the only overlapping marker, which also exhibited a consistent upregulation in association with the development of NI in both cohorts. Previous functional annotation analysis had classified FNBP-1 as molecule with significant enrichment in various brain tissues (P<0.01). CONCLUSION: Our current findings are strongly arguing for intensifying research into the FNBP-1-related mechanisms that may be conferring risk for or resistance to HIV- and/or HCV-related NI.
RESUMEN
OBJECTIVE: To investigate the effect of an intervention in which medical-microbiological laboratories alert general practitioners (GPs) in writing about patients with a chronic hepatitis B or C infection in their practice, urging them to bring these patients under medical surveillance again now that treatment options have improved and guidelines have been revised. DESIGN: Descriptive, prospective. METHOD: All patients who had been diagnosed with hepatitis B or C between 2003 and 2013 on the request of the GP, and for whom diagnostics by an internist, infectious diseases specialist or gastrointestinal/liver specialist had never been requested, were included. The requesting GP received a letter advising them to confirm the diagnosis, and if results were positive to refer the patient to a hepatitis centre. If the GP did not respond, or the healthcare practitioner involved was not the current GP, a written reminder was sent. RESULTS: A total of 515 letters were sent initially; the final response following reminders was 362 (70%). Of these 362 patients, 69 (19%) still had an indication for referral and 45 (64%) were referred to a hepatitis centre. CONCLUSION: The intervention was successful, feasible and relatively simple.
Asunto(s)
Médicos Generales/estadística & datos numéricos , Hepatitis B Crónica/terapia , Hepatitis C Crónica/terapia , Registros Médicos/estadística & datos numéricos , Derivación y Consulta/estadística & datos numéricos , Adulto , Correspondencia como Asunto , Monitoreo Epidemiológico , Femenino , Alemania , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , EscrituraRESUMEN
Patients who use immunosuppressive agents, in particular medication that blocks tumour necrosis factor-a, are at risk for mycobacterial infections. Besides the typical Mycobacterium tuberculosis infection, a lso a typical mycobacterial disease may occur. Here we demonstrate two patients with such atypical mycobacterial infection due to swimming and fishing water contact. We propose that patients, before starting with immunosuppressive therapy, are counselled about risk factors for mycobacterial disease.